Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Germany sees rapid EU approval of AstraZeneca's COVID-19 vaccine

Published 30/12/2020, 11:12
© Reuters. FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

By Kirsti Knolle and Douglas Busvine

BERLIN (Reuters) - Germany expects the European Union to give rapid approval to the coronavirus vaccine developed by Oxford University and AstraZeneca that was cleared for use in Britain on Wednesday, its top vaccines official said.

Berlin's support for AstraZeneca comes as EU member countries seek to fill supply chains for vaccination drives that began last weekend using a shot from Pfizer (NYSE:PFE) and BioNTech - the only one to win EU approval so far.

Germany has made relatively quick headway, reporting a total of 78,000 shots administered, but there have been reports of setbacks with some vaccination centres shutting down temporarily due to supply shortages.

Responding to complaints in the capital Berlin and in the federal states of Brandenburg and Bavaria of delays in delivering the Pfizer vaccine, the Health Ministry said further shipments were due on Jan. 8 and Jan. 18.

Fatalities linked to COVID-19 in Germany hit a record daily high of 1,129 on Wednesday, bringing total deaths to 32,107, as local authorities caught up with a Christmas reporting backlog. Total confirmed cases reached 1.69 million.

Klaus Cichutek, head of the Paul Ehrlich Institute, said that, thanks to the rolling EU review of the AstraZeneca vaccine, it would be possible to take a quick decision once a formal application was submitted.

No such application had been received by the European Medicines Agency (EMA) by Wednesday morning, Cichutek told reporters, but a debate in its councils would follow as soon as it arrived.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"Once the application is submitted a decision can be taken quickly," Cichutek told a news conference.

"THOROUGH AND QUICK"

German Health Minister Jens Spahn urged "a thorough and quick examination" of the AstraZeneca vaccine by EMA, in addition to the expected clearance of a shot from Moderna (NASDAQ:MRNA) in early January.

"Vaccination is the key to getting out of this pandemic," Spahn told reporters.

"Preventing death and suffering is key. It is the key to getting our normal lives back."

Spahn confirmed that Germany still expected to take delivery of 1.3 million doses of the Pfizer shot by the end of the year.Then, after the two consignments in January, weekly shipments of 670,000 doses would follow each Monday, his ministry said.

Even with increased supply going into early 2021, it will take months to inoculate the wider population.

"I can only appeal for patience," he said. "Please don't forget that we have a vaccine ... that is reason enough for joy and optimism."

Amid heightened contagion, continued strong reductions of social contacts would continue to be necessary, officials said.

"It will take months until enough people are vaccinated to reduce the circulation of the virus in the population," said Lothar Wieler, head of the Robert Koch Institute responsible for coordinating Germany's pandemic response.

Federal and regional leaders are due to convene in the New Year to discuss whether to extend lockdown measures imposed before Christmas that are due to remain in force until at least Jan. 10.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.